Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Global Market

0.50USD
27 Jan 2015
Change (% chg)

-- (--)
Prev Close
$0.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
303,057
52-wk High
$3.47
52-wk Low
$0.37

CYTX.OQ

Chart for CYTX.OQ

About

Cytori Therapeutics, Inc. (Cytori) develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. The Company’s research applications include stress, urinary incontinence, wound healing, fistula repair, burn, facial wasting, liver insufficien... (more)
No analyst recommendations are available for CYTX.OQ.

Overall

Beta: 1.08
Market Cap(Mil.): €40.73
Shares Outstanding(Mil.): 92.45
Dividend: --
Yield (%): --

Financials

  CYTX.OQ Industry Sector
P/E (TTM): -- 34.37 40.41
EPS (TTM): -0.52 -- --
ROI: -78.90 10.73 18.28
ROE: -286.17 12.57 19.19
Search Stocks

U.S. government extends contract with Cytori for burn treatment

- The U.S. government has extended a contract with Cytori Therapeutics to develop a cell-derived treatment for burns, the company said on Tuesday.

19 Aug 2014

U.S. government extends contract with Cytori for burn treatment

Aug 19 - The U.S. government has extended a contract with Cytori Therapeutics to develop a cell-derived treatment for burns, the company said on Tuesday.

19 Aug 2014

Cytori suspends enrollment in cell therapy trials

- Cytori Therapeutics Inc said it has suspended enrollments in two trials of its experimental cell therapy for heart failure patients after a safety review.

05 Aug 2014

Cytori suspends enrollment in cell therapy trials

Aug 5 - Cytori Therapeutics Inc said it has suspended enrollments in two trials of its experimental cell therapy for heart failure patients after a safety review.

05 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks